LP 20
Alternative Names: LP-20Latest Information Update: 27 Dec 2022
At a glance
- Originator Lipella Pharmaceuticals
- Class Contrast media; Diagnostic agents; Imaging agents
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Bladder cancer
Most Recent Events
- 27 Dec 2022 Phase-I development for Bladder-cancer(Diagnosis) is ongoing in USA (Lipella Pharmaceuticals pipeline, December 2022)
- 28 May 2022 No recent reports of development identified for phase-I development in Bladder-cancer(Diagnosis) in USA (Intravesicular, Liquid)
- 18 Apr 2019 Phase-I clinical trials in Bladder cancer (Diagnosis) in USA (Intravesicular) (Lipella Pharmaceuticals pipeline, April 2019)